At a glance
- Originator Astellas Pharma
- Class Antihypertensives
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pulmonary hypertension
- Discontinued Hypertension; Pain; Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pulmonary-hypertension in Japan (PO)
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 05 Oct 2004 Preclinical trials in Pulmonary hypertension in Japan (PO)